SAN DIEGO—The inflammatory myopathies are a heterogeneous group of conditions that, although discovered decades ago, continue to challenge rheumatologists in terms of their myriad clinical presentations. In Flexing Strong Science on Weak Muscles: Genetics, Genomics and Autoantibodies in Myositis, two speakers provided exceptionally helpful insights into these conditions, using novel tools for analysis. 6 Types…
SAN DIEGO—At ACR Convergence 2023, Philip Seo, MD, MHS, presented an overview of clinical updates in rheumatology from the past year.
SAN DIEGO—Pain is one of the most common symptoms of rheumatic disease, and this session at ACR Convergence 2023 was dedicated to understanding recent research concerning the relationship between pain and inflammation.
SAN DIEGO—The large vessel vasculitides, including Takayasu’s arteritis and giant cell arteritis, experienced a surge of interest at ACR Convergence 2023. Here, we highlight important points from 10 of the studies presented at this conference.
Updates from the ACR Convergence 2023 Review Course, part 6 SAN DIEGO—The pre-conference Review Course at ACR Convergence 2023, held Saturday, Nov. 11, and moderated by Noelle Rolle, MBBS, assistant professor in the Division of Rheumatology, associate program director of the Rheumatology Fellowship at the Medical College of Georgia, Augusta University, and Julia Schwartzmann-Morris, MD,…
SAN DIEGO—Thomas Ortel, MD, PhD, chief, Division of Hematology, Department of Medicine, Duke University School of Medicine, Durham, N.C., discussed thrombotic microangiopathies at ACR Convergence 2023. With a variety of causes, including autoimmune diseases, the connection with rheumatology is evident.
SAN DIEGO—Recognition as an ACR Master is one of the highest honors the College bestows. This year, the ACR conferred the honor on 25 distinguished rheumatologists.
SAN DIEGO—Award presentations & artificial intelligence topped the list in the ACR Convergence 2023 Opening Session & Keynote Lecture on Nov. 11.
Dr. Aletaha discussed several studies of interventions in pre-RA, including SAVE, STIVEA, PROMPT, PRAIRI, TREAT EARLIER and STOP-RA.
EULAR 2023 (MILAN)—Over the past several years, a plethora of new treatments for patients with rheumatoid arthritis (RA) has emerged, while older treatments still play a large role in therapy for many patients. At the EULAR 2023 session titled Rheumatoid Arthritis: New Small Molecules and Old DMARDs, several speakers presented abstracts comparing different treatment effects…